Company Overview

VenoStent is a clinical-stage therapeutic medical device company developing SelfWrap, a bioabsorbable perivascular wrap designed to improve arteriovenous fistula outcomes for chronic kidney disease patients requiring hemodialysis. Founded in Houston, Texas, and backed by Y Combinator (W20), the company raised $22.8M total funding including a $20M Series A in June 2024 led by Good Growth Capital and IAG Capital Partners with $4M from Norwest Venture Partners, plus a $3.6M SBIR Phase II Grant from the NIH. VenoStent initiated its first clinical sites and enrolled the first patients in its 200-patient randomized controlled trial (RCT) in multiple US centers in 2024.

Revenue
$22.8M
Loading News...
Loading Timeline...
Loading Culture...
Loading Leadership...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Strong Challenger

VenoStent is an established challenger with significant market presence and competitive offerings in Healthcare.

Frequently Asked Questions

AI Visibility Rankings

How VenoStent performs in AI search results

AI Rank
?
Track your position
Platforms
5
ChatGPT, Gemini, Claude...
Visibility
?
Your mention rate
Premium Feature

Unlock AI Visibility Tracking for VenoStent

See exactly how VenoStent ranks across ChatGPT, Gemini, Perplexity, Claude, and Grok. Get actionable insights to improve your AI search performance.

Real-time Rankings
Track your position daily
Competitive Intel
See how you compare
Platform Breakdown
Per-AI performance
Actionable Insights
Optimize your visibility
Start Tracking for Free

Join 1,000+ brands · Free 7-day trial · No credit card required

Want to improve your AI visibility? Track performance across all major AI platforms.
Compare with Other Brands

Compare with Other Brands

See how VenoStent stacks up against competitors with our detailed comparison tool.

Start Comparison